Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Chemotherapy +/- Radiation for Lung Cancer
Recruiting1 awardPhase 2
Bronx, New York
This trial tests a combination of nivolumab, chemotherapy, and sometimes targeted radiation in patients with a specific type of lung cancer that can be surgically removed. The treatment aims to shrink the tumor and kill cancer cells, making surgery more effective. Nivolumab with chemotherapy has been approved by the FDA as the first immunotherapy-based treatment for non-small cell lung cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.